Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of BI 456906 in overweight or obese Chinese adults
CTR20234328Phase 3Completed
- Sponsor
- ——/ 勃林格殷格翰(中国)投资有限公司
- Start
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of survodutide in obesity, Overweight, type 2 diabetes mellitus (T2DM), hypertension (HTN), dyslipidemia, sponsored by ——/ 勃林格殷格翰(中国)投资有限公司. Started Jan 2024; status: completed.
02
Drugs
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on CTR20234328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234328.